It is proposed that an important function of leptin is to con®ne the storage of triglycerides (TG) to the adipocytes, while limiting TG storage in nonadipocytes. Excess TG deposition in nonadipocytes leads to impairment of functions, increased ceramide formation, which triggers nitric oxide-mediated lipotoxicity and lipoapoptosis. The fact that TG content in nonadipocytes normally remains within a very narrow range irrespective of excess caloric intake, while TG content of adipocytes rises, is consistent with a system of fatty acid (FA) homeostasis in nonadipose tissues. When leptin is de®cient or leptin receptors are dysfunctional, TG content in nonadipose tissues such as pancreatic islets, heart and skeletal muscle, can increase 10 ± 50-fold, suggesting that leptin controls the putative homeostatic system for intracellular TG. The fact that function and viability of nonadipocytes is compromised when their TG content rises above normal implies that normal homeostasis of their intracellular FA is critical for prevention of complications of obesity. FA overload of skeletal muscle, myocardium and pancreatic islets cause, respectively, insulin resistance, lipotoxic heart disease and adipogenic type 2 diabetes. All can be completely prevented by treatment with antisteatotic agents such as troglitazone. In diet-induced obesity, leptin signaling is normal initially and lipotoxic changes are at ®rst prevented; later, however, post-receptor leptin resistance appears, leading to dysfunction and lipoapoptosis in nonadipose tissues, the familiar complications of obesity.
Introduction
Long chain fatty acids (FA) provide the building blocks for the phospolipid bilayers of cell membranes and for the intracellular phospholipid messengers upon which normal cell function depends. It is likely, therefore, that all cells maintain a small stockpile of FA, stored as triacylglycerol (TG), for these essential housekeeping functions. But this small internal reserve is too precious to be used as a fuel. Not until the evolution of the adipocyte, with its unlimited storage capacity for TG and its ability to redistribute the stored FA on demand to nonadipose tissues, could this most ef®cient of fuels be fully exploited. The ability to preload calories and to store them as TG may be one of the most transforming events in all of evolution, improving survival during famine and permitting migratory activity of many species including man, as proposed in the`thrifty gene' hypothesis of Neel. 1 
Lipotoxic diseases
Caloric preloading, a temporary increase in caloric intake, was intended to result in temporary increase in fat stores to meet the anticipated environmental challenges mentioned. However, in the latter portion of the twentieth century in the United States, radical environmental changes took place: a permanent increase in caloric intake, attributable to the aggressive marketing of high-energy, high-fat foods, coupled with the advent of immobilizing technological innovations, such as television, computers and automobiles, drastically increased the daily caloric balance. The result was an unprecedented epidemic of obesity.
FA over¯ow hypothesis
Lipotoxic complications of obesity have been attributed to an over¯ow of FA from adipocytes to nonadipocytes and deposition of the unneeded FA excess as TG. 2 Circulating free fatty acids (FFA), higher in obese individuals than in lean persons, 3`¯i pop' across the plasma membranes of all cells. 4 Unoxidized FA will be esteri®ed to TG. While the enlarged stores of TG are probably inert and therefore in themselves harmless to the cells, the TG excess may be hydrolyzed back to fatty acyl CoA at a rate that exceeds the oxidative needs of the cell, driving the unoxidized excess into deleterious pathways of FA metabolism, such as de novo ceramide formation. 5 
Normal FA homeostasis in nonadipocytes
Recent studies in rodents indicate that FA homeostasis in nonadipocytes is regulated by leptin, which operates as an antisteatotic hormone. 6 Four lines of evidence support this hypothesis: (1) on the very ®rst day of a high-fat diet, plasma leptin levels rise progressively and continue to increase in parallel with the accumulation of fat in adipocytes; (2) during such overfeeding, the TG content of nonadipose tissues remains at low levels, while TG content in adipocytes rises progressively; (3) in rodent models lacking leptin activity as a result of either leptin de®ciency or defective leptin receptors, TG content of nonadipocytes is very high, even on a relatively normal fat intake; and (4) if normal leptin receptors are overexpressed in the islets of leptin receptor-defective rats, the ectopic accumulation of TG is reduced. Leptin, therefore, appears to meet the criteria for an antisteatotic hormone.
Lipotoxicity secondary to abnormal leptin receptors (OB-R)
In the obese faafa ZDF rat a Glu 269? Pro mutation involving the extracellular domain of all OB-R isoforms appears to block leptin action. 7, 8 These rats exhibit widespread steatosis involving skeletal muscle, heart, pancreas, pancreatic islets and liver. 6 In b-cells, this is associated with extensive alterations of the mitochondria and apoptosis, 9 which can be blocked by transgenic overexpression of a functional wild-type OB-Rb in the islets. 10 In the absence of a functional OB-R, these abnormalities can also be completely prevented by measures that lower the ectopic accumulation of FA in nonadipose tissues (troglitazone treatment) 9 or which block nitric oxide (NO) formation (nicotinamide or aminoguanidine treatment). 11 This implies that lipoapoptosis requires FA-induced overproduction of NO.
Leptin normally protects nonadipocytes from steatosis by raising the rate of b oxidation of long chain FA above the level required for their own energy needs. It does this by permitting FA to upregulate PPARa, 12 which in turn increases the transcription of the oxidative enzymes, acyl CoA oxidase (ACO) of peroxisomes and carnitine palmitoyl transferase-1 (CPT-1) of mitochondria. The unneeded energy thereby generated is presumably dissipated as heat, as a consequence of upregulation of the uncoupling proteins (UCP) 1 and 2. 13 Ectopic accumulation of TG in nonadipose tissues is thus minimized as long as the leptin system is operative ( Figure 1A) .
The loss-of-function mutation in the leptin receptor that occurs in faafa ZDF rats completely inactivates this system. Fatty acids no longer upregulate PPARa, ACO and CPT-1. Rather, PPARa is expressed at subnormal levels and, in its stead, PPARg, a lipogenic transcription factor, is expressed at high levels. 12 In addition, the lipogenic enzymes, acetyl CoA carboxylase (ACC) and fatty acid synthase (FAS), are expressed at increased levels. This promotes increased lipogenesis from glucose and increased esteri®cation of excess FA to TG 14 ( Figure 1B) .
Mechanism of lipoapoptosis
The lipoapoptotic pathway resembles in its distal portion the autoimmune apoptotic pathway through In obesity with impaired FA homeostasis, plasma FFA and TG are increased. FA traverse plasma membranes freely and enter all cells. There, they must bind to a fatty acid-binding protein andaor be activated to FA CoA. The intracellular FA CoA will therefore exceed the oxidative requirements for the cell and will enter other metabolic pathways, causing some of the complications of obesity. We postulate that increased TG content of certain tissues, such as smooth muscle, may reduce their compliance and give rise to some of the complications of obesity.
Lipotoxicity in obesity RH Unger and L Orci which cytokines are believed to bring about destruction of b cells in type 1 diabetes. Only the proximal segments of the pathways appear to differ. In autoimmune destruction of b cells the increased ceramide is thought to be the result of sphingomyelin breakdown as a consequence of enhanced sphingomyelinase activity. 15 Ceramide, in turn, activates nuclear factor Kappa B, which upregulates inducible nitric oxide synthesis (iNOS). In autoimmune diabetes the increase in nitric oxide (NO) is a major factor in the complete destruction of all b cells that takes place.
The lipoapoptotic pathway differs from the autoimmune pathway in that the increase of ceramide is the result of de novo ceramide synthesis. Each molecule of ceramide contains two molecules of longchain FA; the ®rst step in ceramide synthesis is the condensation of palmitoyl CoA and serine to form dihydrosphingosine. This reaction is catalyzed by the enzyme serine palmitoyl transferase (SPT). In islets of obese ZDF rats with defective OB-R, expression of this enzyme is increased, 16 Figure 2 ). Transgenic overexpression of normal OB-Rb into these islets will reduce the TG content and correct SPT overexpression. Ceramide formation is thereby reduced and apoptosis completely prevented. 9 In other words, when a large excess of FA is trapped within pancreatic islets (steatosis), ceramide may reach cytotoxic levels. This will rid the islets of b cells that can no longer carry out their normal function. As long as formation of new functional b cells keeps pace with the rate of lipo-apoptosis, islet function may remain adequate; when, however, apoptosis exceeds the rate of replacement, diabetes will ensue.
Prevention of lipoapoptosis in vitro and in vivo
One can reduce lipoapoptosis in vitro by blocking ceramide synthesis, either with the competitive inhibitor of SPT, L-cycloserine, or the fungal derivative, fumonisin B 1 . 16 In addition, inhibitors of NO production, such as nicotinamide and aminoguanidine, effectively block the lipotoxic and lipoapoptotic effects of FA in vitro. The thiazolidine dione compound, troglitazone, also protects islets in vitro, presumably through its antisteatotic effect.
Both troglitazone 9 and the iNOS inhibitors, aminoguanidine and nicotinamide, 11 have been used therapeutically to prevent diabetes in ZDF rats. When administered from the age of 6 weeks (before the onset of diabetes) until 12 weeks of age, at which time all untreated animals have become diabetic, all three agents are remarkably effective in preventing the diabetes and preserving the normal architecture and functional characteristics of the pancreatic islets.
Troglitazone lowers the islet TG content and prevents the loss of b cells that otherwise occurs. 9 The ®brosis and deformation of the islets is averted, together with the loss of GLUT-2 and glucose-responsive insulin secretion (Figure 3 ). Most strikingly, the profound alterations of mitochondria observed in the b cells of untreated ZDF rats do not occur 9 ( Figure 4 ). The mechanism of this dramatic action of troglitazone is not known. The lipogenic effect of the drug in islets is paradoxical inasmuch as this agent has lipogenic activity in adipocytes.
The iNOS inhibitors aminoguanidine and nicotinamide also completely prevent the b cell destruction, loss of b cell function and the hyperglycemia that occurs in sham-treated controls 11 ( Figure 5 ). However, they appear to work at a more distal level in the lipoapoptotic pathway by blocking NO production.
Thus, the pancreatic islets, because of their sensitivity to apoptotic factors, appear to be vulnerable to the ectopic accumulation of TG resulting from failure of the normal system of intracellular FA homeostasis. It seems possible that other complications of obesity involving nonadipose tissues may be the result of a similar mechanism. 
